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Abstract
Objectives: To evaluate the immunological and viral consequences of planned treatment interruptions (PTI) in children with
HIV.
Design: This was an immunological and virological sub-study of the Paediatric European Network for Treatment of AIDS
(PENTA) 11 trial, which compared CD4-guided PTI of antiretroviral therapy (ART) with continuous therapy (CT) in children.
Methods: HIV-1 RNA and lymphocyte subsets, including CD4 and CD8 cells, were quantified on fresh samples collected
during the study; CD45RA, CD45RO and CD31 subpopulations were evaluated in some centres. For 36 (18 PTI, 18 CT)
children, immunophenotyping was performed and cell-associated HIV-1 DNA analysed on stored samples to 48 weeks.
Results: In the PTI group, CD4 cell count fell rapidly in the first 12 weeks off ART, with decreases in both naı¨ve and memory
cells. However, the proportion of CD4 cells expressing CD45RA and CD45RO remained constant in both groups. The
increase in CD8 cells in the first 12 weeks off ART in the PTI group was predominantly due to increases in RO-expressing
cells. PTI was associated with a rapid and sustained increase in CD4 cells expressing Ki67 and HLA-DR, and increased levels
of HIV-1 DNA.
Conclusions: PTI in children is associated with rapid changes in CD4 and CD8 cells, likely due to increased cell turnover and
immune activation. However, children off treatment may be able to maintain stable levels of naı¨ve CD4 cells, at least in
proportion to the memory cell pool, which may in part explain the observed excellent CD4 cell recovery with re-
introduction of ART.
Citation: Klein N, Sefe D, Mosconi I, Zanchetta M, Castro H, et al. (2013) The Immunological and Virological Consequences of Planned Treatment Interruptions in
Children with HIV Infection. PLoS ONE 8(10): e76582. doi:10.1371/journal.pone.0076582
Editor: Derya Unutmaz, New York University, United States of America
Received May 3, 2013; Accepted August 26, 2013; Published October 23, 2013
Copyright:  2013 Klein et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Paediatric European Network for Treatment of AIDS (PENTA). Professor Nigel Klein was funded by Great Ormond Street Children’s Charity. The work has
also received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement n. 201057 (PENTA LABNET). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: n.klein@ucl.ac.uk
" Membership of the Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team is provided in the Acknowledgments.
Introduction
The Paediatric European Network for Treatment of AIDS
(PENTA) 11 trial was a pilot study comparing CD4-guided
planned treatment interruptions (PTI) of antiretroviral therapy
(ART) with continuous therapy (CT) in HIV-1-infected children
who had achieved long-term plasma HIV-1 RNA suppression and
substantial immune reconstitution. The key findings were that no
serious clinical outcomes occurred in children undergoing PTIs,
[1] and that following re-introduction of ART, the PTI group
recovered CD4 and re-suppressed viral load to the same extent as
the CT group [2].
The results of studying a range of structured treatment
interruption strategies in Adults infected with HIV have generally
been disappointing [3–7]. Patients exhibit lower CD4 counts,
experience more infections, have higher mortality rates, and are at
greater risk of virological failure upon ART reinstitution. Although
PENTA 11 was only a small pilot study, there are reasons why
children may be able to better tolerate or even benefit from the
PTI. Firstly, the recovery rates of naı¨ve CD4 T cells during ART
are significantly higher for children under 3 years of age than for
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older children, and ten to forty times higher than for adults, [8,9]
most likely because children have a higher thymic output than
adults [10]. Secondly, largely as a result of immunological
immaturity, infants have higher rates of viral replication than
older children and adults [11]. However if virus can be successfully
suppressed with ART during early childhood, better viral control
may be achieved in the context of both a more mature immune
system and good thymic output, if, or when, therapy is interrupted
[12].
Thus interrupting therapy, and re-exposing children to HIV, at
a point where there is a large population of naive T cells and the
immune system is relatively more mature than at primary (vertical)
infection may have different consequences from adults. We
therefore performed in-depth immunological and virological
analyses in a subset of children randomised to CT and PTI to
address this question.
Methods
PENTA 11 was an open, multicentre, randomised, phase II,
trial (ISRCTN36694210) in HIV-1 infected children aged 2–
15 years, on any ART regimen containing three or more drugs
which they had taken for $24 weeks. Eligibility criteria included
the two most recent plasma HIV-1 RNA to be ,50 copies/ml,
(screening and prescreening), and CD4% to be $30% (ages 2–
6 years) or $25% and CD4 count $500 cells/mm3 (7–15 years)
[1]. Children were randomised to either CT or to an open strategy
of CD4-guided PTI. ART was restarted if confirmed CD4% was
less than 20% or more than 48 weeks had been spent off ART. A
substudy to examine the influence of PTI on immunological and
virological parameters was performed on stored samples in a
subset of children.
HIV-1 RNA and CD4 and CD8 lymphocyte subsets were
quantified locally on fresh samples collected at 0, 2, 4, 8, 12 weeks
after enrolment and then 12-weekly. In some centres, CD45RA
and CD45RO subpopulations of CD4 and CD8 cells were also
evaluated on fresh samples (including for the 36 children in the
substudy described below). In centres able to separate and store
cells, an additional 10 ml of whole blood was collected in EDTA at
each visit; peripheral blood mononuclear cells (PBMC) were
isolated by density gradient centrifugation, divided into aliquots,
and frozen.
Immunophenotyping
In 20 UK children (11CT, 9PTI) and 12 Italian children (5CT,
7PTI), aliquots were thawed and cell suspensions incubated with
antibodies: anti-CD3 [fluorescein isothiocyanate (FITC)], anti-
CD4 [peridinin chlorophyll protein (PerCP)], anti-CD8 (PerCP),
anti-CD38 [phyoerythrin (PE)], anti-CD45RA [allophycocyanin
(APC)], and anti-CD31 (PE), all from Becton-Dickinson (Becton-
Dickinson Biosciences Pharmingen, San Diego, CA, USA).
Appropriate isotypic controls (mouse IgG1-PE and IgG2b-APC)
were used to evaluate non-specific staining. Cells were then
washed with Automacs Buffer (Milteny Biotec Inc. Auburn, CA,
USA) and resuspended in PBS supplemented with 1% parafor-
maldehyde. All samples were analyzed by four-color flow
cytometry using a FACS Calibur (Becton-Dickinson) with a
488 nm argon-ion laser and a 635 nm red diode laser. 50,000
events were collected in the lymphocyte gate using morphological
parameters (Forward and Side scatter). Data were processed using
Table 1. Baseline Characteristics.
Main trial Substudy Substudy Overall
CT PTI CT PTI p-value p-value
(n=53) (n=56) (n=18) (n=18) CT vs PTI
main trial vs
substudy
Male (%) 22 (42%) 27 (48%) 9 (50%) 10 (56%) 0.7 0.4
Age (years)
median [IQR] 9.9 [6.4,12.3] 9.0 [6.7,11.9] 9.9 [5.8,11.6] 9.0 [6.0,10.9] 1.0 0.6
$2 years to ,7 years 15 (28%) 17 (30%) 6 (33%) 7 (39%)
$7 years to ,11 years 18 (34%) 22 (40%) 8 (44%) 8 (44%) 0.9 0.3
$11 years to ,16 years 20 (38%) 17 (31%) 4 (22%) 3 (17%)
CDC disease stage
% N/A/B/C 17/23/26/34 20/34/28/18 1/4/7/6 3/4/8/3 0.6 0.4
HIV-1 RNA:
$50 copies/ml at baselinea 3 (6%) 8 (14%) 2 (11%) 3 (17%) 0.6 0.5
CD4 parameters, median [IQR]
CD4% of total lymphocytes 37 [34,40] 37 [33,42] 35 [33,38] 37 [33,44] 0.1 1.0
CD4 (cells/mm3) 965 [741,1222] 967 [844,1302] 999 [786,1151] 989 [860,1321] 0.4 0.9
CD8 parameters, median [IQR]
CD8% of total lymphocytes 31 [27,34] 33 [26,37] 29 [25,32] 25 [23,33] 0.3 0.02
CD8 (cells/mm3) 790 [592,1020] 871 [615,1070] 765 [540,1010] 643 [544,961] 0.5 0.2
aAll children had HIV-1 RNA ,50 copies/ml at screening and pre-screening. HIV-1 RNA was assumed to be at least 50 copies/ml at baseline for 11 children [six children
(two CT and four PTI) ,100 copies/ml, two children (one CT and one PTI) ,200 copies/ml and three children (PTI) .=200 copies/ml: range 240–2430 copies/ml. Note:
chi-squared test and t-test were used to compare categorical and continuous characteristics respectively.
CT = continuous therapy; PTI = planned treatment interruption; IQR = interquartile range; CDC = Centers for Disease Control and Prevention.
doi:10.1371/journal.pone.0076582.t001
Treatment Interruption in HIV Infected Children
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CellQuest Pro Software (Becton-Dickinson) and analyzed using
the Summit Software version 4.3 (Dako, Glostrup, Denmark).
Viral load quantification
In 16 Italian children (7CT, 9PTI) (12 with immunophenotyp-
ing plus 4 others with insufficient samples for immunophenotyp-
ing), cell-associated HIV-1 DNA was measured in PBMC by real
time PCR, as previously described [13]. The HIV-1 copy number
was normalized against b-actin copies, and final results expressed
as HIV-1 DNA copies/106 PBMC.
Quantification of lipopolysaccharide
In the same 16 children with cell-associated HIV-1 DNA
measured, lipopolysaccharide (LPS) was determined in plasma
samples diluted five-fold with endotoxin-free water and then
heated to 70uC for 10 min to inactivate plasma proteins. Plasma
LPS was quantified using a chromogenic assay (Limolus Amebo-
cyte Lysate QCL-1000), as previously described [14].
Statistical analysis
Baseline characteristics of children in the substudy were
compared by randomised group, and children in the main study
were compared to those in the substudy, using chi-squared test for
categorical variables and the t-test for continuous variables.
Changes from baseline in laboratory measurements were estimat-
ed using normal regression of actual measurements adjusting for
baseline. Generalised estimating equations were used for global
tests of differences between randomised groups over 48 weeks,
adjusted for baseline [15]. Relative changes from baseline in HIV-
1 DNA were estimated using normal regression of log10
transformed measurements. Unavailable data due to non-atten-
dance, failure to collect the sample, or failure to obtain satisfactory
data upon thawing of the frozen PBMCs were treated as missing at
random. In the PTI group, measurements taken after restarting
ART were excluded; see [1] for details of children restarting ART
during the study. All analysis used Stata statistical software, version
10.1 (StataCorp., College Station, Texas, USA).
Role of funding source
Representatives of the sponsor, the PENTA Foundation, were
part of the study team and therefore were involved in study design,
coordination, data collection, data analysis, data interpretation,
and writing of the report. The corresponding author had full
access to all the data in the study and had final responsibility for
the decision to submit for publication.
Ethics
The protocol for this study was approved by the ethics
committee for each participating centre. Patients included in this
sub study were recruited from the UK, approval from Trent
MREC, and from Italy, approval from Comitato Etico per la
Sperimentazione, Azienda Ospedaliera di Padova. All parents/
guardians gave written consent, and children gave written assent,
according to their age and knowledge of HIV status.
Results
109 children (53CT, 56PTI) were included in the main PENTA
11 analysis, randomised between November 2004 and December
2006. At baseline the median age was 9 (range 2–16) years,
median CD4% 37% (interquartile range (IQR): 33,41) and CD4
990 (763,1248) cells/mm3. No child died or had a new CDC C
diagnosis. One child (2%) in CT versus four (7%) in PTI
(difference +5%, 95% confidence interval (CI) 22% to +13%;
p = 0.2) reached a CD4 outcome (3PTI CD4% ,15% (aged
,7 years), 1CT 1PTI CD4% ,15% and CD4 count ,200 cells/
mm3 (aged $7 years) [1]. Of 56 children randomized to PTI, 19
reached the CD4-guided ART restart criteria between 6 and
42 weeks after stopping ART, 32 restarted ART only because they
Figure 1. Change in HIV-1 RNA, CD4 and CD8 cells from baseline in the PTI group. Change in HIV-1 RNA from baseline for all children in the
trial in the PTI (planned treatment interruption) group off ART (antiretroviral therapy) and children in the substudy in the PTI group off ART (a).
Change in CD4 and CD8 from baseline for all children in the trial in the PTI (planned treatment interruption) group off ART (antiretroviral therapy) and
in the CT (continuous ART) group (b). Changes from baseline were estimated using normal regression of actual measurements adjusting for baseline
using the overall mean at randomisation as the reference category.
doi:10.1371/journal.pone.0076582.g001
Treatment Interruption in HIV Infected Children
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had been off ART for 48 weeks, and four restarted for other
reasons.
Baseline characteristics of the 36 children in the substudy
(median age 9 (range 3–16) years, median CD4% 37% (IQR:
33,42) and CD4 count 990 (835,1276) cells/mm3) were similar to
all children in the study, although CD8% was slightly lower
(Table 1). Similarly, there were no differences in baseline
characteristics between the CT and PTI children within the
substudy (Table 1). Of 18 children in the PTI substudy group, 4
reached the CD4-guided ART restart criteria 8, 12, 19 and
37 weeks after stopping ART, 12 restarted ART only because they
had been off ART for 48 weeks and two restarted for other
reasons at weeks 16 and 87.
Changes in HIV-1 RNA, CD4 and CD8 cells
As previously described [1], HIV-1 RNA increased rapidly in
the PTI group over the first 4 weeks off ART, reaching a peak at
,12 weeks (mean (95% CI) change 0–12 weeks 2.6 (2.4,2.8) log10
copies/ml) and remaining constant to 48 weeks (Figure 1a). CD4
cell count also fell sharply in the PTI group (mean (95% CI)
change 0–12 weeks 2312 (2377,2248) cells/mm3), and then
stabilized (Figure 1b). CD8 cell count increased to reach a peak at
eight weeks (mean (95% CI) change 0–8 weeks 664 (473,854)
cells/mm3) then gradually declined during the following 40 weeks
(Figure 1b). In comparison, CD4 and CD8 cell counts in patients
remaining on therapy (CT group) remained stable over the same
Figure 2. Changes in CD45RA, CD45RO and CD45A+CD31+ cells. Changes in absolute numbers of CD45RA cells (a), CD45RO cells (b) and CD4
RA and RO cells as a % of CD4 cells, for children in the trial where of CD4 sub-populations were evaluated (including the children in the substudy) (c).
Change in CD45RA+ CD31+ cells from baseline for children in the substudy (d). CT = continuous ART (antiretroviral therapy), PTI = planned
treatment interruption (off ART). Changes from baseline were estimated using normal regression of actual measurements adjusting for baseline using
the overall mean at randomisation as the reference category.
doi:10.1371/journal.pone.0076582.g002
Treatment Interruption in HIV Infected Children
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48 week period (CD4 and CD8 CT versus PTI global p,0.001)
(Figure 1b).
CD4 cell loss is due to reductions in both naı¨ve and
memory cells
The loss of CD4 cells following PTI was the result of a decrease
in both naı¨ve and memory cells; mean (95% CI) change 0–4 weeks
was 2204 (2305, 2104) and 298 (2147, 250) cells/mm3
respectively (Figure 2a and 2b, data were available for ,25–50%
of children at each time point). Interestingly, as a consequence, the
proportion of CD4 cells expressing CD45RA and CD45RO
remained approximately constant throughout the first 48 weeks in
both the CT and PTI (off ART) groups (Figure 2c, data were
available for,25–50% of children at each time point, CD45RA%
CT versus PTI global p = 0.3, CD45RO% CT versus PTI global
p = 0.6). CD4 cells stained for CD31 and CD45RA (substudy
children only) revealed four populations of cells (Figure S1). The
largest population of cells (approximately 49%) were positive for
both CD31 and CD45RA (possibly representing recent thymic
emigrants cells). This subpopulation rapidly declined within the
first 4 weeks off ART in the PTI group; mean (95% CI) change 0–
4 weeks was 2230 (2304, 2156) versus +29 (252,+110) cells/
mm3 in CT group, p,0.001 (Figure 2d, global p,0.001).
Reductions were seen in the other three cell populations, including
the CD45RA- CD31- and CD45RA- CD31+ memory cells (data
not shown).
Increases in CD8 cells following PTI are due to increases
in CD8 memory cells.
Increases in CD8 cells following PTI seen in Figure 1b were
predominantly due to increases in RO-expressing memory cells;
mean (95% CI) change 0–8 weeks was +288 (+99,+476) versus
233 (2237,+171) cells/mm3 in CT (p = 0.04) (Figure 3, global
p,0.001). This was concurrent with a small but persistent
reduction in RA-expressing CD8 cells; mean 95% CI change 0–
8 weeks was 2119 (2213, 226) versus 219 (2125,+88) cells/
mm3 in CT (p = 0.2). However, the ratio of RO to RA cells
remained constant between 8 and 48 weeks off ART.
PTI is associated with immune activation and
proliferation
PTI was associated with a rapid increase in CD4 cells expressing
Ki67 and HLA-DR 2 weeks after stopping ART, which was
sustained subsequently. This was most marked in the CD4
CD45RA-CD31- (memory) population; mean (95% CI) change in
percentage of cells expressing Ki67 0–4 weeks was 2.7%
(1.7%,3.8%) in PTI versus 20.4% (21.3%,+0.5%) CT,
p = 0.004 (Figure 4a, global p,0.001); for HLA-DR, the mean
(95% CI) change 0–4 weeks was 1.0% (20.7%,+2.6%) PTI versus
22.3% (24.4%,20.3%) CT, p = 0.04, (Figure 4b, global
p = 0.005). A similar trend was seen in the other subpopulations
of CD4 cells, particularly CD45RA-CD31+ cells, which persisted
throughout the 48 week period studied. There was also a trend
towards increased expression of CD38 in the CD8 population in
the PTI group, although numbers were small: mean (95% CI)
change 0–4 weeks was +6.7% (24.6%,+17.9%) in PTI (n = 3)
versus +2.1% (28.8%,+13.0%) CT (n = 5).
In the PTI group, mean (SD) LPS levels were 99 (25) pg/ml at
baseline and increased by mean (95% CI) +15 (+5,+25) pg/ml by
four weeks off ART versus +18 (+5,+30) CT, p = 0.7. Increases
were sustained to 48 weeks, mean (95% CI) change 0–48 weeks
was +81 (+54,+108) PTI versus 24 (229,+21) pg/ml CT,
p = 0.004. (Figure 4c, global p,0.001).
PTI may be associated with increased HIV-1 DNA
By four weeks, levels of HIV DNA per 106 PBMC had
increased in the PTI group; mean (95% CI) relative change 0–
4 weeks in log10 HIV DNA per 10
6 PBMC was +36%
(+14%,+59%) in PTI versus 22% (226%,+22%) in CT,
p = 0.04 (Figure 5, global p = 0.03). This trend continued over
48 weeks of follow-up, although small numbers of measurements
at later time points make it difficult to draw reliable conclusions.
Discussion
In this first pilot study to document the detailed immunological
and virological responses to PTI in children with chronic HIV-1
infection, the main findings are that after stopping ART, there
were rapid changes in viraemia and cell-associated virus, CD4 and
CD8 cell numbers, affecting both naive and memory populations,
and CD4 cell activation and proliferation. However, all of these
parameters had stabilised by 12 weeks and remained similar for
the remaining 48-week period off ART.
The substantial drop in CD4 cell count following PTI was
expected and was broadly similar to the known response to
treatment interruption, planned or otherwise in children and
adults [16,17]. It would appear, however, that there are subtle, but
potentially important, differences in CD4 cell dynamics between
children and adults following PTI. The studies of Thiebaut [17]
and Davey [18] indicate that, in contrast to our study, adults
appear to exhibit a more pronounced progressive decline in CD4
cells. This occurs in spite of increased CD4 cell turnover [18],
indicating that in adults, this is insufficient to keep pace with the
CD4 cell loss. In contrast, in children it would appear that
increased cell turnover, as indicated by the elevated CD4 Ki67
expression, and possibly higher thymic output, is sufficient to
maintain CD4 counts after the initial drop in CD4 cells following
treatment cessation.
Figure 3. Change in CD8 RA and RO cells from baseline. Change
in CD8 RA and RO cells from baseline for children in the substudy. CT =
continuous ART (antiretroviral therapy), PTI = planned treatment
interruption (off ART). Changes from baseline were estimated using
normal regression of actual measurements adjusting for baseline using
the overall mean at randomisation as the reference category.
doi:10.1371/journal.pone.0076582.g003
Treatment Interruption in HIV Infected Children
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Unexpectedly, both naı¨ve and memory cell numbers were
depleted following treatment interruption, such that the propor-
tion of CD4 cells expressing CD45RA and CD45RO remained
constant throughout the first 48 weeks in both CT and PTI
groups. It is difficult to assess how our observations compare with
adults. The limited data that does exists in adults on relative
changes in naı¨ve/memory cell populations is based on short-term
periods of structured treatment interruption (STI) in contrast to
the longer period of 48 weeks used in this study. It would appear
that in adults, throughout the course of periods of STI, the
predominant populations affected are memory cells, with variable
changes in the naı¨ve populations [19,20].
It has been established that in adults, changes in CD4 following
ART initiation are predominantly due to redistribution of memory
cells, followed later by an increase in the naı¨ve cell population
[21]. This biphasic reconstitution is less pronounced in children
with the increase in CD4 cells emanating predominantly from the
naı¨ve CD4 pool [22–24]. Naı¨ve CD4+ T cell numbers are
maintained by a balance between production of naı¨ve cells and
their loss by death or differentiation. The chemokine IL-7 is a key
homeostatic regulator of naı¨ve T cell numbers, along with self-
MHC stimulation [25]. The mechanisms by which memory cells
are maintained are less well defined [25], but survival and self-
renewing proliferation are likely to be controlled by competition
for homeostatic resources such as cytokines, e.g. IL15, and TCR-
self-peptide/MHC interactions [26]. In this study, the rapid
decline in both naive and memory cells and re-stabilisation of both
compartments at a new lower CD4 count implies that regardless of
what may be driving the CD4 cell loss, a degree of homeostasis is
achieved for both CD4 naı¨ve and memory compartments,
irrespective of the CD4 cell decline, which is then maintained
for at least 48 weeks.
To investigate if PTI caused a selective loss of recent thymic
emigrants, we stained CD4 cells with CD31, also known as platelet
endothelial cell adhesion molecule-1. CD31+ CD45RA+ cells
have a high T cell receptor excision circle (TREC) content, and
Figure 4. Change in % Ki67, HLA-DR and LPS from baseline. Change in % Ki67 (a) and % HLA-DR (b) in CD45RA- CD31- cells and in LPS (c)
from baseline for children in the substudy. CT = continuous ART (antiretroviral therapy), PTI = planned treatment interruption (off ART). Changes
from baseline were estimated using normal regression of actual measurements adjusting for baseline using the overall mean at randomisation as the
reference category.
doi:10.1371/journal.pone.0076582.g004
Treatment Interruption in HIV Infected Children
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are enriched with cells that have recently emigrated from the
thymus. CD31–CD45RA+ cells represent a population of naı¨ve
cells with a lower TREC content in which CD31 expression is
reduced in response to homeostatic expansion [27]. Two RA-
populations defined by CD31 expression also exist. In healthy
individuals the largest population is CD31-, with ,5% expressing
CD31. The latter population appears to have a lower replicative
history than the CD31- cells [28]. It is possible to maintain the
overall proportions of naı¨ve and memory populations whilst seeing
substantial shifts in the four populations of CD4 cells as defined by
CD31 expression. For example, expansion of CD31- naı¨ve cells
may increase to compensate for a loss of recent thymic emigrants.
Our data did not find evidence that this was the case and
confirmed that the predominant populations affected by PTI were
the CD31+CD45RA+ and CD31-CD45RA- cells.
The very rapid decline in CD4 cells combined with the
observation that CD31+CD45RA+ cells were not the only
population to diminish, would make a reduction in thymic output
unlikely as the primary cause of the CD4 cell decline. A more
plausible mechanism is immune activation, now a well recognised
driver of CD4 cell death [29] which is also seen in adults following
PTI [30,31]. We observed a very rapid increase in both Ki67 and
HLA-DR expression after PTI, which is indicative of increased cell
turnover and CD4 cell activation. Both Ki67 and HLA-DR
remained elevated during the period off ART, most marked in the
memory populations. Taken together, our results suggest that
while the CD4 count remained stable after 12 weeks of PTI, it was
being maintained because of, or indeed in spite of, increased cell
turnover. If the CD4 count after 12 weeks represents a new ‘CD4
set point’, it would thus appear to be maintained by an increase in
cell proliferation, a concurrent increase in cell death and possibly a
change in thymic output.
Immune activation has been described in adults not taking ART
and has been linked to long-term adverse effects [32]. It is unclear
if the level and duration of immune activation and increased CD4
cell turnover has long-term effects on the immune system and on
other organs, such as the cardiovascular system in children. Two
observations may be pertinent to this question. First, we observed
increased levels of LPS following PTI. This could conceivably be
because of CD4 cell depletion within the gastrointestinal tract,
resulting in increased circulating microbial components, or
modulation of intestinal flora [33,34]. If increased LPS does
indeed represent immune injury within the gastrointestinal tract,
this may be irreversible. However evidence against irreversible
immune injury comes from two observations. Firstly, that the
proportion of RA to RO cells remained constant up to 48 weeks
off ART. The absence of a selective decline in the naı¨ve
population may indicate that thymic output is being maintained
at pre-PTI levels. In ongoing work in a Ugandan cohort, we have
found that the proportion of CD45RA+CD31+ cells prior to
starting therapy is the best indicator of eventual immune recovery
[35,36]. Secondly, two years after the end of the PENTA 11 trial,
there were no statistically significant differences in CD4 cell counts
between the continuous and treatment interrupted groups [2].
Detailed immunological and virological studies are ongoing and
should provide further insights into the long-term effects of PTI in
children, many of whom will interrupt ART at some stage in
childhood, given the considerable challenges ART presents to
families.
In contrast to CD4 cells, there was a rapid rise in CD8 memory
cells after ART interruption. The most plausible explanation is
that this represents expansion of CD8 clones directed against HIV
[37]. It is also possible that some of the increase is due to
proliferation of CD8 cells directed against non-HIV epitopes, such
as herpes viruses, or as a result of bystander activation. The
sustained increase in CD8 cells indicates that the drivers of the
CD8 expansion were persistent, and the observed increase in
CD8+CD38+ expression with PTI would be consistent with
increased immune activation [38]. A lack of CD8 effectiveness in
controlling HIV may be reflected in the increase in HIV-1 DNA
observed as early as 4 weeks and persisting for the duration of PTI.
It will be important to ascertain if this apparent increase in HIV-1
DNA persists even after ART reintroduction, which we are now
studying.
A limitation of this study was the small patient population
sampled. This was due to both low numbers enrolled in the sub
study, and technical failures, namely inadequate numbers of cells
or poor recovery following thawing. A further limitation was only
having the capacity at the time, to analyse four colours by flow
cytometry. This restricted the range of markers that could be
analysed, such as CD27 and CCR7 to further characterise the
naı¨ve and memory populations.
Overall, PTI in children results in rapid changes in CD4 and
CD8 cells, which are associated with increased cell turnover and
immune activation. The CD4 cell decline appears to be due to
changes in both naı¨ve and memory cell populations, such that
their ratio remains stable throughout the period of treatment
interruption. Taken together, these results suggest that, in the face
of ongoing immune activation as a result of PTI, these children are
able to maintain their circulating naı¨ve CD4 cells, at least in
proportion to their circulating memory cell pool. This may
indicate that PTI of up to 48 weeks in children during mid-
childhood who have been on ART for .5 years, is not necessarily
associated with irreversable degradation of the naı¨ve cell pool.
This may explain the degree of CD4 cell recovery which we have
observed following ART re-introduction, whereby CD4 counts
and % among children in the PTI group ‘caught up’ with children
on CT by 2 years back on ART [2]. In the light of our findings, it
is interesting that children who received multiple cycles of PTI,
followed by ART, showed evidence of enhanced immunity to
Figure 5. Relative change in HIV DNA copies/106 PBMC from
baseline. Relative change in HIV DNA copies/106 PBMC from baseline
for children in the substudy. CT = continuous ART (antiretroviral
therapy), PTI = planned treatment interruption (off ART), PBMC =
peripheral blood mononuclear cells.
doi:10.1371/journal.pone.0076582.g005
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HIV, and lower plasma RNA during episodes of treatment
interruption. This may indicate that there may even be some
potential benefits from controlled exposure to viral antigens [39].
Further studies are required to fully evaluate the long-term
consequences of PTI in children before the benefits and risks can
be objectively assessed. However, while PTI is not recommended,
it could be considered when the risk of unplanned treatment
interruptions is high.
Conclusion
This is the first study to document in detail the impact of
treatment interruption on CD4 and CD8 dynamics in the context
of a randomised clinical trial. The data presented indicate that
changes occur within weeks, and include a reduction in naı¨ve and
memory CD4 cell populations and an increase in CD8 memory
cells. These changes persist for the remainder of the 48 weeks
following treatment interruption. These changes were associated
with an increase in CD4 and CD8 activation and proliferation,
which persisted for the duration of the period of treatment
interruption. By the end of 48 weeks the ratio of naı¨ve to memory
cells was similar to that found at baseline and may indicate that
changes in T cell dynamics were not necessarily irreversible. This
would be consistent with the excellent long-term recovery of CD4
cells following re-initiation of treatment.
Supporting Information
Figure S1 Representative FACS Profiles. Dot Plot: CD4
cells stained for CD31 and CD45RA revealed four populations of
cells. The largest population of cells were positive for both CD31
and CD45RA. Representative Histograms are shown for Ki67 and
HLA-DR for CT = continuous ART (antiretroviral therapy), and
PTI = planned treatment interruption (off ART).
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